
Vesalius Therapeutics
Vesalius Therapeutics is a company pioneering a radical approach to common disease drug development. Its precision platform, Continuum Discoveryâ„¢, integrates AI/ML analysis of human phenotypic data with human genetics and proprietary human-based experimental models to develop transformational therapies for patients suffering from common illnesses. The platform defines causal disease phenotypes linked to multigene circuits and unique points of intervention that drive rapid development of differentiated therapies. Combined with gene circuit-derived biomarkers and human-based translational models, Vesalius’ Continuum Discoveryâ„¢ platform delivers efficient translation into smaller, shorter clinical trials with a higher probability of success. Vesalius was founded in 2019 by »Æ¹ÏÊÓÆµapp. For more information visit , or follow us on and .
Latest News from Vesalius Therapeutics
- Yasir Al-Wakeel Appointed CEO of Vesalius Therapeutics and CEO-Partner of »Æ¹ÏÊÓÆµapp 09.16.2025
- Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease 11.12.2024
- Vesalius Therapeutics Announces Leadership Transition 03.07.2024